TOP HEADLINES

Featured Story

Bayer, Boehringer lead rapid rise in pharma's social media output

Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.

WuXi invests $15M in DNAnexus to fuel push into China

DNAnexus has snagged $15 million from WuXi PharmaTech in a Series D round. The deal will see DNAnexus bring its cloud-based genomics platform to China and pair it with WuXi NextCODE's offering.

Lilly, Novartis and Pfizer give trial-patient matching tech to TrialReach

Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.

Edico and Intel set sights on real-time whole genome analysis

Edico Genome has hooked up with Intel in an attempt to shave more minutes off the time it takes to analyze a whole genome. The partnership brings together Edico's NGS analysis hardware and the Intel Xeon microprocessors that reside in many servers used in genomics.

Quest, LabCorp team to build database of cancer genetics

Quest Diagnostics has teamed up with French human health research institute Inserm to pool and share BRCA1 and BRCA2 genetic data. LabCorp has signed up as the first participant in the program, giving it a sizable reach from day one.

MORE NEWS

From Our Sister Sites

FiercePharma Manufacturing

Injectable drug specialist Hospira, which is being bought by Pfizer, blew past analysts' projections for its Q1 earnings today but its manufacturing issues continue to be a drag. The FDA just last week said Hospira had issued a recall of an anesthetic because iron particles had been found in some vials.

FierceBiotech

Merck execs used their quarterly review today to confirm that the troubled drug Bridion (sugammadex) has once again been rejected at the FDA. This is the drug's third stiff arm at the agency,...